What is Jumpcode Genomics?
Jumpcode Genomics operates at the intersection of molecular biology and data science, specializing in the enhancement of next-generation sequencing (NGS) data usability. By developing programmable endonuclease enzymes and specialized depletion kits, the company effectively removes uninformative molecules from sequencing libraries. This process significantly improves the signal-to-noise ratio in critical applications such as single-cell analysis, microbiome characterization, infectious disease detection, and whole transcriptome profiling. By transforming raw sequencing output into high-fidelity data, Jumpcode Genomics empowers academic institutions and commercial researchers to accelerate discovery and improve diagnostic accuracy in genomics.
How much funding has Jumpcode Genomics raised?
Jumpcode Genomics has raised a total of $24.5M across 2 funding rounds:
Series A
$3.5M
Series B
$21M
Series A (2018): $3.5M, investors not publicly disclosed
Series B (2021): $21M led by Baird Capital, LYZZ Capital Advisors, and Arboretum Ventures LLC
Key Investors in Jumpcode Genomics
Baird Capital
Baird Capital is a private equity and venture capital firm that invests in founder-led B2B tech and services companies globally, providing operational support and deep institutional knowledge to foster growth.
LYZZ Capital Advisors
Undisclosed investor participating in the funding round.
Arboretum Ventures LLC
Undisclosed investor participating in the funding round.
What's next for Jumpcode Genomics?
With the recent influx of capital, Jumpcode Genomics is well-positioned to transition from a specialized technology provider to a broader enterprise-level player in the genomics infrastructure market. The strategic focus will likely center on scaling the manufacturing of its depletion kits and expanding its commercial footprint to meet the rising demand for high-resolution genomic data. As the company matures, it is expected to leverage its proprietary enzyme platform to forge deeper partnerships within the clinical diagnostics and pharmaceutical research sectors, further cementing its role as an essential component of the modern NGS ecosystem.
See full Jumpcode Genomics company page
